Endometrial regenerative cells for treatment of heart failure: A new stem cell enters the clinic

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Bockeria, Leo ^a   Bogin, Vladimir ^b   Bockeria, Olga ^a   Le, Tatyana ^a   Alekyan, Bagrat ^a   Woods, Erik J ^c   Brown, Amalia A ^d   Ichim, Thomas E ^b   Patel, Amit N ^d  

^a Bacoulev Institute for Cardiovascular Surgery   (Russian Federation)

^b Medistem Inc   (United States)

^c General Biotechnology   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; ANGIOPOIETIN; BETA1 INTEGRIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CD146 ANTIGEN; CD18 ANTIGEN; CD59 ANTIGEN; CD9 ANTIGEN; ENDOGLIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERMES ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; MATRIX METALLOPROTEINASE; NEUROTROPHIN 3; OCTAMER TRANSCRIPTION FACTOR 4; PLACEBO; PLATELET DERIVED GROWTH FACTOR BB; STROMELYSIN; TELOMERASE; THY 1 ANTIGEN; VASCULOTROPIN;

ANGIOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; DUCHENNE MUSCULAR DYSTROPHY; ENDOMETRIAL REGENERATIVE CELL; ENDOMETRIOSIS; HEART FAILURE; HEART INJURY; HEART MUSCLE CELL; HUMAN; LIMB ISCHEMIA; MESENCHYMAL STEM CELL; MINIMALLY INVASIVE PROCEDURE; MULTIPLE SCLEROSIS; NONHUMAN; PATIENT SAFETY; PROTEIN EXPRESSION; PROTEIN SECRETION; REGENERATIVE MEDICINE; REVIEW; STEM CELL EXPANSION; STEM CELL TRANSPLANTATION; THERAPY EFFECT;

ANIMALS; CELL TRANSPLANTATION; ENDOMETRIUM; FEMALE; HEART FAILURE; HUMANS; MODELS, ANIMAL; REGENERATIVE MEDICINE;

EID: 84874461037     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-56     Document Type: Review

References (94)

1. Pelacho B, Prosper F. Stem cells and cardiac disease: where are we going?. Curr Stem Cell Res Ther 2008, 3(4):265-276. 10.2174/157488808786734015, 19075756.
2. Choi YH. Cardiac cell therapies: the next generation. Cardiovasc Ther 2011, 29(1):2-16. 10.1111/j.1755-5922.2010.00191.x, 20946322.
3. Menasche P. Myoblast transplantation for heart failure. Lancet 2001, 357(9252):279-280. 10.1016/S0140-6736(00)03617-5, 11214133.
4. Hamano K. Local implantation of autologous bone marrow cells for therapeutic angiogenesis in patients with ischemic heart disease: clinical trial and preliminary results. Jpn Circ J 2001, 65(9):845-847. 10.1253/jcj.65.845, 11548889.
5. Strauer BE. [Intracoronary, human autologous stem cell transplantation for myocardial regeneration following myocardial infarction]. Deutsche medizinische Wochenschrift 2001, 126(34-35)):932-938.
6. Zhao Q. Randomized study of mononuclear bone marrow cell transplantation in patients with coronary surgery. Ann Thorac Surg 2008, 86(6):1833-1840. 10.1016/j.athoracsur.2008.08.068, 19021989.
7. Stamm C. Intramyocardial delivery of CD133+ bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: safety and efficacy studies. J Thorac Cardiovasc Surg 2007, 133(3):717-725. 10.1016/j.jtcvs.2006.08.077, 17320570.
8. Hendrikx M. Recovery of regional but not global contractile function by the direct intramyocardial autologous bone marrow transplantation: results from a randomized controlled clinical trial. Circulation 2006, 114(1 Suppl):I101-I107.
9. Patel AN. Surgical treatment for congestive heart failure with autologous adult stem cell transplantation: a prospective randomized study. J Thorac Cardiovasc Surg 2005, 130(6):1631-1638. 10.1016/j.jtcvs.2005.07.056, 16308009.
10. Ahmadi H. Safety analysis and improved cardiac function following local autologous transplantation of CD133(+) enriched bone marrow cells after myocardial infarction. Curr Neurovasc Res 2007, 4(3):153-160. 10.2174/156720207781387141, 17691968.
11. Mocini D. Autologous bone marrow mononuclear cell transplantation in patients undergoing coronary artery bypass grafting. Am Heart J 2006, 151(1):192-197. 10.1016/j.ahj.2005.02.001, 16368317.
12. Donndorf P. Intramyocardial bone marrow stem cell transplantation during coronary artery bypass surgery: A meta-analysis. J Thorac Cardiovasc Surg 2011, 142(4):911-920. 10.1016/j.jtcvs.2010.12.013, 21376346.
13. Meyer GP. Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. Eur Heart J 2009, 30(24):2978-2984. 10.1093/eurheartj/ehp374, 19773226.
14. Yousef M. The BALANCE Study: clinical benefit and long-term outcome after intracoronary autologous bone marrow cell transplantation in patients with acute myocardial infarction. J Am Coll Cardiol 2009, 53(24):2262-2269. 10.1016/j.jacc.2009.02.051, 19520249.
15. Lunde K. Anterior myocardial infarction with acute percutaneous coronary intervention and intracoronary injection of autologous mononuclear bone marrow cells: safety, clinical outcome, and serial changes in left ventricular function during 12-months' follow-up. J Am Coll Cardiol 2008, 51(6):674-676. 10.1016/j.jacc.2007.10.032, 18261689.
16. Beitnes JO. Long-term results after intracoronary injection of autologous mononuclear bone marrow cells in acute myocardial infarction: the ASTAMI randomised, controlled study. Heart 2009, 95(24):1983-1989. 10.1136/hrt.2009.178913, 19833610.
17. Cao F. Long-term myocardial functional improvement after autologous bone marrow mononuclear cells transplantation in patients with ST-segment elevation myocardial infarction: 4 years follow-up. Eur Heart J 2009, 30(16):1986-1994. 10.1093/eurheartj/ehp220, 2726958, 19508995.
18. Meyer GP. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation 2006, 113(10):1287-1294. 10.1161/CIRCULATIONAHA.105.575118, 16520413.
19. Janssens S. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 2006, 367(9505):113-121. 10.1016/S0140-6736(05)67861-0, 16413875.
20. Meluzin J. Three-, 6-, and 12-month results of autologous transplantation of mononuclear bone marrow cells in patients with acute myocardial infarction. Int J Cardiol 2008, 128(2):185-192. 10.1016/j.ijcard.2007.04.098, 17764767.
21. Yao K. Repeated autologous bone marrow mononuclear cell therapy in patients with large myocardial infarction. Eur J Heart Fail 2009, 11(7):691-698. 10.1093/eurjhf/hfp062, 19420003.
22. Assmus B. Clinical outcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction. Circ Heart Fail 2010, 3(1):89-96. 10.1161/CIRCHEARTFAILURE.108.843243, 19996415.
23. Zhang C. Efficacy and safety of intracoronary autologous bone marrow-derived cell transplantation in patients with acute myocardial infarction: insights from randomized controlled trials with 12 or more months follow-up. Clin Cardiol 2010, 33(6):353-360. 10.1002/clc.20745, 20556805.
24. Hare JM. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 2009, 54(24):2277-2286. 10.1016/j.jacc.2009.06.055, 3580848, 19958962.
25. Hare JM. Comparison of Allogeneic vs Autologous Bone Marrow-Derived Mesenchymal Stem Cells Delivered by Transendocardial Injection in Patients With Ischemic Cardiomyopathy: The POSEIDON Randomized Trial. JAMA 2012, 12;308(22):2369-2379.
26. Huang Y. Effect of fluid shear stress on cardiomyogenic differentiation of rat bone marrow mesenchymal stem cells. Arch Med Res 2010, 41(7):497-505. 10.1016/j.arcmed.2010.10.002, 21167388.
27. Behfar A. Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction. J Am Coll Cardiol 2010, 56(9):721-734. 10.1016/j.jacc.2010.03.066, 2932958, 20723802.
28. Rogers TB. Mesenchymal stem cells stimulate protective genetic reprogramming of injured cardiac ventricular myocytes. J Mol Cell Cardiol 2011, 50(2):346-356. 10.1016/j.yjmcc.2010.09.001, 20837021.
29. Schittini AV. Human cardiac explant-conditioned medium: soluble factors and cardiomyogenic effect on mesenchymal stem cells. Exp Biol Med 2010, 235(8):1015-1024.
30. Peran M. Human cardiac tissue induces transdifferentiation of adult stem cells towards cardiomyocytes. Cytotherapy 2010, 12(3):332-337. 10.3109/14653240903548202, 20230311.
31. Hatzistergos KE. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res 2010, 107(7):913-922. 10.1161/CIRCRESAHA.110.222703, 3408082, 20671238.
32. Macdonald GI, Augello A, De Bari C. Mesenchymal stem cells: Re-establishing immunological tolerance in autoimmune rheumatic diseases. Arthritis Rheum 2011, 63(9):2547-2557. 10.1002/art.30474, 21647863.
33. Guo J. Xenogeneic Immunosuppression of Human Umbilical Cord Mesenchymal Stem Cells in a Major Histocompatibility Complex (MHC)-mismatched allogeneic acute graft-versus-host disease murine model. Eur J Haematol 2011, 87(3):235-243. 10.1111/j.1600-0609.2011.01635.x, 21535158.
34. Walter DH. Impaired CXCR4 signaling contributes to the reduced neovascularization capacity of endothelial progenitor cells from patients with coronary artery disease. Circ Res 2005, 97(11):1142-1151. 10.1161/01.RES.0000193596.94936.2c, 16254213.
35. Prianishnikov VA. On the concept of stem cell and a model of functional-morphological structure of the endometrium. Contraception 1978, 18(3):213-223. 10.1016/S0010-7824(78)80015-8, 569035.
36. Kearns M, Lala PK. Bone marrow origin of decidual cell precursors in the pseudopregnant mouse uterus. J Exp Med 1982, 155(5):1537-1554. 10.1084/jem.155.5.1537, 2186682, 7069373.
37. Kyo S. Telomerase activity in human endometrium. Cancer Res 1997, 57(4):610-614.
38. Williams CD. A prospective, randomized study of endometrial telomerase during the menstrual cycle. J Clin Endocrinol Metabol 2001, 86(8):3912-3917.
39. Oshita T. Telomerase activation in endometrial epithelial cells by paracrine effectors from stromal cells in primary cultured human endometrium. Int J Mol Med 2004, 13(3):425-430.
40. Cervello I. Identification, characterization and co-localization of label-retaining cell population in mouse endometrium with typical undifferentiated markers. Hum Reprod 2007, 22(1):45-51.
41. Schwab KE, Chan RW, Gargett CE. Putative stem cell activity of human endometrial epithelial and stromal cells during the menstrual cycle. Fertil Steril 2005, 84(Suppl 2):1124-1130.
42. Chan RW, Schwab KE, Gargett CE. Clonogenicity of human endometrial epithelial and stromal cells. Biol Reprod 2004, 70(6):1738-1750. 10.1095/biolreprod.103.024109, 14766732.
43. Schwab KE, Hutchinson P, Gargett CE. Identification of surface markers for prospective isolation of human endometrial stromal colony-forming cells. Hum Reprod 2008, 23(4):934-943. 10.1093/humrep/den051, 18305000.
44. Meng X. Endometrial regenerative cells: a novel stem cell population. J Transl Med 2007, 5:57. 10.1186/1479-5876-5-57, 2212625, 18005405.
45. Patel AN. Multipotent menstrual blood stromal stem cells: isolation, characterization, and differentiation. Cell Transplant 2008, 17(3):303-311. 10.3727/096368908784153922, 18522233.
46. Niklaus AL. Effect of estrogen on vascular endothelial growth/permeability factor expression by glandular epithelial and stromal cells in the baboon endometrium. Biol Reprod 2003, 68(6):1997-2004.
47. Niklaus AL. Expression of vascular endothelial growth/permeability factor by endometrial glandular epithelial and stromal cells in baboons during the menstrual cycle and after ovariectomy. Endocrinology 2002, 143(10):4007-4017. 10.1210/en.2002-220385, 12239112.
48. Albrecht ED. Acute temporal regulation of vascular endothelial growth/permeability factor expression and endothelial morphology in the baboon endometrium by ovarian steroids. J Clin Endocrinol Metabol 2003, 88(6):2844-2852.
49. Heryanto B, Girling JE, Rogers PA. Intravascular neutrophils partially mediate the endometrial endothelial cell proliferative response to oestrogen in ovariectomised mice. Reproduction 2004, 127(5):613-620. 10.1530/rep.1.00161, 15129017.
50. Gargett CE, Rogers PA. Human endometrial angiogenesis. Reproduction 2001, 121(2):181-186. 10.1530/rep.0.1210181, 11226042.
51. Zhang J. Natural killer cell-triggered vascular transformation: maternal care before birth?. Cell Mol Immunol 2011, 8(1):1-11. 3079746, 20711229.
52. Elsheikh E. Cyclic variability of stromal cell-derived factor-1 and endothelial progenitor cells during the menstrual cycle. Int J Mol Med 2011, 27(2):221-226.
53. Robb AO. Influence of menstrual cycle on circulating endothelial progenitor cells. Hum Reprod 2009, 24(3):619-625.
54. Lemieux C, Cloutier I, Tanguay JF. Menstrual cycle influences endothelial progenitor cell regulation: a link to gender differences in vascular protection?. Int J Cardiol 2009, 136(2):200-210. 10.1016/j.ijcard.2008.04.054, 18644636.
55. Murphy MP. Allogeneic endometrial regenerative cells: an "Off the shelf solution" for critical limb ischemia?. J Transl Med 2008, 6:45. 10.1186/1479-5876-6-45, 2533293, 18713449.
56. Cui CH. Menstrual blood-derived cells confer human dystrophin expression in the murine model of Duchenne muscular dystrophy via cell fusion and myogenic transdifferentiation. Mol Biol Cell 2007, 18(5):1586-1594. 10.1091/mbc.E06-09-0872, 1855042, 17314403.
57. Hida N. Novel cardiac precursor-like cells from human menstrual blood-derived mesenchymal cells. Stem Cells 2008, 26(7):1695-1704. 10.1634/stemcells.2007-0826, 18420831.
58. Taguchi A. Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model. J Clin Invest 2004, 114(3):330-338. 484977, 15286799.
59. Borlongan CV. Menstrual blood cells display stem cell-like phenotypic markers and exert neuroprotection following transplantation in experimental stroke. Stem Cells Dev 2010, 19(4):439-452. 10.1089/scd.2009.0340, 3158424, 19860544.
60. Wang H. Comparison of endometrial regenerative cells and bone marrow stromal cells. J Transl Med 2012, 10:207. 10.1186/1479-5876-10-207, 3504519, 23038994.
61. Han X. Inhibition of intracranial glioma growth by endometrial regenerative cells. Cell Cycle 2009, 8(4):606-610. 10.4161/cc.8.4.7731, 19197154.
62. Zhong Z. Feasibility investigation of allogeneic endometrial regenerative cells. J Transl Med 2009, 7:15. 10.1186/1479-5876-7-15, 2649897, 19232091.
63. Ichim TE. Mesenchymal stem cells as anti-inflammatories: implications for treatment of Duchenne muscular dystrophy. Cell Immunol 2010, 260(2):75-82. 10.1016/j.cellimm.2009.10.006, 19917503.
64. Ichim TE. Combination stem cell therapy for heart failure. International archives of medicine 2010, 3(1):5. 10.1186/1755-7682-3-5, 3003238, 20398245.
65. Perin EC. Comparison of intracoronary and transendocardial delivery of allogeneic mesenchymal cells in a canine model of acute myocardial infarction. J Mol Cell Cardiol 2008, 44(3):486-495. 10.1016/j.yjmcc.2007.09.012, 18061611.
66. Robinson SW. Arterial delivery of genetically labelled skeletal myoblasts to the murine heart: long-term survival and phenotypic modification of implanted myoblasts. Cell Transplant 1996, 5(1):77-91. 10.1016/0963-6897(95)02016-0, 8665080.
67. Suzuki K. Development of a novel method for cell transplantation through the coronary artery. Circulation 2000, 102(19 Suppl 3):III359-III364.
68. Suzuki K. Intracoronary infusion of skeletal myoblasts improves cardiac function in doxorubicin-induced heart failure. Circulation 2001, 104(12 Suppl 1):I213-I217.
69. Musialek P. Randomized transcoronary delivery of CD34(+) cells with perfusion versus stop-flow method in patients with recent myocardial infarction: Early cardiac retention of (m)Tc-labeled cells activity. J Nucl Cardiol 2011, 18(1):104-116. 10.1007/s12350-010-9326-z, 3032199, 21161463.
70. Musialek P. Transcoronary stem cell delivery using physiological endothelium-targeting perfusion technique: the rationale and a pilot study involving a comparison with conventional over-the-wire balloon coronary occlusions in patients after recent myocardial infarction. Kardiol Pol 2006, 64(5):489-498. discussion 499.
71. Noyez L. Retrograde versus antegrade delivery of cardioplegic solution in myocardial revascularization. A clinical trial in patients with three-vessel coronary artery disease who underwent myocardial revascularization with extensive use of the internal mammary artery. J Thorac Cardiovasc Surg 1993, 105(5):854-863.
72. Boekstegers P. Selective suction and pressure-regulated retroinfusion: an effective and safe approach to retrograde protection against myocardial ischemia in patients undergoing normal and high risk percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1998, 31(7):1525-1533. 10.1016/S0735-1097(98)00135-1, 9626830.
73. Pohl T. Retroinfusion-supported stenting in high-risk patients for percutaneous intervention and bypass surgery: results of the prospective randomized myoprotect I study. Catheter Cardiovasc Interv 2004, 62(3):323-330. 10.1002/ccd.20060, 15224298.
74. Incorvati RL. Clinical applications of coronary sinus retroperfusion during high risk percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1993, 22(1):127-134. 10.1016/0735-1097(93)90826-M, 8509532.
75. Lokmic Z, Mitchell GM. Visualisation and stereological assessment of blood and lymphatic vessels. Histol Histopathol 2011, 26(6):781-796.
76. Rohde D. Infiltration of both T cells and neutrophils in the skin is accompanied by the expression of endothelial leukocyte adhesion molecule-1 (ELAM-1): an immunohistochemical and ultrastructural study. J Invest Dermatol 1992, 98(5):794-799. 10.1111/1523-1747.ep12499959, 1373748.
77. Anderson SI. ICAM-1 expression and leukocyte behavior in the microcirculation of chronically ischemic rat skeletal muscles. Microvasc Res 2006, 71(3):205-211. 10.1016/j.mvr.2006.03.003, 16647725.
78. Habazettl H. Selectins and beta 2-integrins mediate post-ischaemic venular adhesion of polymorphonuclear leukocytes, but not capillary plugging, in isolated hearts. Pflugers Archiv: European journal of physiology 1999, 438(4):479-485. 10.1007/s004240051065, 10519141.
79. Lesley J. TSG-6 modulates the interaction between hyaluronan and cell surface CD44. J Biol Chem 2004, 279(24):25745-25754. 10.1074/jbc.M313319200, 15060082.
80. Henschler R, Deak E, Seifried E. Homing of Mesenchymal Stem Cells. Transfusion medicine and hemotherapy: offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie 2008, 35(4):306-312.
81. Ruster B. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood 2006, 108(12):3938-3944. 10.1182/blood-2006-05-025098, 16896152.
82. Hart C. Expression and function of homing-essential molecules and enhanced in vivo homing ability of human peripheral blood-derived hematopoietic progenitor cells after stimulation with stem cell factor. Stem Cells 2004, 22(4):580-589. 10.1634/stemcells.22-4-580, 15277703.
83. Rampon C. Molecular mechanism of systemic delivery of neural precursor cells to the brain: assembly of brain endothelial apical cups and control of transmigration by CD44. Stem Cells 2008, 26(7):1673-1682. 10.1634/stemcells.2008-0122, 18450824.
84. Bachrach E. Muscle engraftment of myogenic progenitor cells following intraarterial transplantation. Muscle Nerve 2006, 34(1):44-52. 10.1002/mus.20560, 16634061.
85. Boekstegers P. Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins. Gene Ther 2000, 7(3):232-240. 10.1038/sj.gt.3301079, 10694800.
86. Alino SF. Naked DNA delivery to whole pig cardiac tissue by coronary sinus retrograde injection employing non-invasive catheterization. J Gene Med 2010, 12(11):920-926. 10.1002/jgm.1510, 20967894.
87. Youssef EA. Enhancing myocardial plasmid expression by retrograde coronary venous delivery. Catheter Cardiovasc Interv 2005, 65(4):528-534. 10.1002/ccd.20450, 16003788.
88. Raake P. Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins: comparison with surgical and percutaneous intramyocardial gene delivery. J Am Coll Cardiol 2004, 44(5):1124-1129. 10.1016/j.jacc.2004.05.074, 15337228.
89. von Degenfeld G. Selective pressure-regulated retroinfusion of fibroblast growth factor-2 into the coronary vein enhances regional myocardial blood flow and function in pigs with chronic myocardial ischemia. J Am Coll Cardiol 2003, 42(6):1120-1128. 10.1016/S0735-1097(03)00915-X, 13678941.
90. Suzuki K. Targeted cell delivery into infarcted rat hearts by retrograde intracoronary infusion: distribution, dynamics, and influence on cardiac function. Circulation 2004, 110(11 Suppl 1):II225-II230.
91. George JC. Transvenous intramyocardial cellular delivery increases retention in comparison to intracoronary delivery in a porcine model of acute myocardial infarction. J Interv Cardiol 2008, 21(5):424-431. 10.1111/j.1540-8183.2008.00390.x, 19012733.
92. Thompson CA. Percutaneous transvenous cellular cardiomyoplasty. A novel nonsurgical approach for myocardial cell transplantation. Journal of the American College of Cardiology 2003, 41(11):1964-1971.
93. Tuma J. Safety and feasibility of percutaneous retrograde coronary sinus delivery of autologous bone marrow mononuclear cell transplantation in patients with chronic refractory angina. J Transl Med 2011, 9:183. 10.1186/1479-5876-9-183, 3215661, 22029669.
94. Raake PW. Cardio-specific long-term gene expression in a porcine model after selective pressure-regulated retroinfusion of adeno-associated viral (AAV) vectors. Gene Ther 2008, 15(1):12-17. 10.1038/sj.gt.3303035, 17943147.